Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement of regulatory and sales milestones. The transaction, which could reach ...

Novartis is buying Anthos Therapeutics from Blackstone’s drug development division, as it makes a bet on an experimental drug aimed at preventing strokes in patients with an irregular heart rhythm.

Novartis is buying Anthos Therapeutics from Blackstone’s drug development division, as it makes a bet on an experimental drug aimed at preventing strokes in patients with an irregular heart rhythm.

To boost its cardiovascular pipeline, Novartis has announced the acquisition of the company it co-founded with Blackstone ...

The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...

By Ludwig Burger and Ariane Luthi (Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a ...

Novartis is acquiring Anthos Therapeutics for up to $3.08 billion, adding abelacimab, a late-stage anticoagulant, to its ...

Novartis has agreed to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical ...

Artificial intelligence could be used to prescribe medications to patients — if a new bill makes its way through Congress ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

In his next chief executive gig after securing the $14 billion acquisition of Karuna Therapeutics Inc., Bill Meury has now locked in another big biotech deal.

Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.